Vitamin D Testing
Europe
Updated
Reviewed by Vidhi Upadhyay
Europe Antimicrobial Resistance Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$387.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $542.3 Mn | — | — |
| 2025 (base) | $574.3 Mn | +$32.0 Mn | — |
| 2026 (forecast) | $608.2 Mn | +$33.9 Mn | +5.9% |
| 2027 (forecast) | $644.1 Mn | +$35.9 Mn | +12.1% |
| 2028 (forecast) | $682.1 Mn | +$38.0 Mn | +18.8% |
| 2029 (forecast) | $722.3 Mn | +$40.2 Mn | +25.8% |
| 2030 (forecast) | $764.9 Mn | +$42.6 Mn | +33.2% |
| 2031 (forecast) | $810.1 Mn | +$45.1 Mn | +41.1% |
| 2032 (forecast) | $857.9 Mn | +$47.8 Mn | +49.4% |
| 2033 (forecast) | $908.5 Mn | +$50.6 Mn | +58.2% |
| 2034 (forecast) | $962.1 Mn | +$53.6 Mn | +67.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $574.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $962.1 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Technology, setting and end user (see all) |
| Key players | bioMérieux SA, BD (Becton, Dickinson), Beckman Coulter (Danaher), Accelerate Diagnostics, Inc., Thermo Fisher Scientific Inc. (see all) |
| Regulator in Europe | EU MDRSource: European Commission, medical devices. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Antimicrobial resistance diagnostics show which antibiotics will work against an infection, helping doctors avoid ineffective drugs.
Key segments of the antimicrobial Resistance Diagnostics market include technology (Automated AST Systems, Molecular Resistance Tests and Rapid Phenotypic AST) and setting (Hospital Labs and Reference Labs).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antimicrobial Resistance Diagnostics market.
New vaccines, rapid tests and public-private funding for neglected diseases give the antimicrobial Resistance Diagnostics market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antimicrobial Resistance Diagnostics market.
The antimicrobial Resistance Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.[1] In the countries we cover here, medical devices are regulated by ANSM (France)[2], BfArM (Germany)[3], Ministry of Health (Italy)[4], Roszdravnadzor (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8]
[1] European Commission, medical devices. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Ministry of Health. Checked 14 Nov 2026.
[5] Roszdravnadzor. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how antimicrobial Resistance Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.
What doctors and scientists are doing in Antimicrobial Resistance Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe
Europe
Europe
Europe
Europe
Europe
Digital Health · Europe
Healthcare Services · Europe
Pharmaceuticals · Europe
OTC & Nutraceuticals · Europe
Pharmaceuticals · Europe
OTC & Nutraceuticals · Europe